Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACE-MATE
2024-514794-22-01Phase 2Withdrawn
- Sponsor
- Imperial College London
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing Tezspire with Placebo (2 arms). Primary endpoint: Remission at week 24. Planned start May 2025; status: withdrawn.
02
Drugs
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2024-514794-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514794-22-01.